Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Elisa Becze, BA, ELS, Editor


Lab-developed antibodies using a single-chain diabody format can target TP53 or RAS variants in solid tumors and T-cell receptor (TCR) variants in blood cancers, researchers reported in study findings published in ScienceScience Immunology, and Science Translational Medicine, respectively.

View Article @

ONS Voice Articles

ONS's member magazine articles.

View All Voice Articles